
Zenas BioPharma, Inc.: shareholders and insiders
Price
$23.85
November 20, 2026Market cap $1.6B
What Ploutos Investor adds for Zenas BioPharma
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Sep 2, 2026, from their own Form 4 filings.
Bought on the market
$11M
4 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $11M by 4 people·no sales
- 2025: no buys, no sales
- 2026: bought $11M by 4 people, no sales
- Feb 5, 2026Joseph L FarmerPresident and Chief Operating OfficerKind
- Feb 5, 2026Jennifer A. FoxChief Business Officer and Chief Financial OfficerKind
- May 18, 2026Leon O Moulder JrChief Executive OfficerKind
- Apr 29, 2026Leon O Moulder JrChief Executive OfficerKind
- Apr 28, 2026Leon O Moulder JrChief Executive OfficerKind
- Mar 31, 2026Hongbo LuKind
- Mar 31, 2026Tomas KiselakKind
- Mar 31, 2026Hongbo LuKind
- Mar 31, 2026Leon O Moulder JrChief Executive OfficerKind
- Mar 30, 2026Leon O Moulder JrChief Executive OfficerKind
- Feb 13, 2026Patricia L AllenKind
- Feb 12, 2026Patricia L AllenKind
- Feb 12, 2026Patricia L AllenKind
- Feb 12, 2026Patricia L AllenKind
- Feb 11, 2026Hongbo LuKind
- Feb 2, 2026Leon O Moulder JrChief Executive OfficerKind
- Jan 9, 2026Leon O Moulder JrChief Executive OfficerKind
- Jan 8, 2026Leon O Moulder JrChief Executive OfficerKind
- Jan 7, 2026Leon O Moulder JrChief Executive OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Joseph L FarmerPresident and Chief Operating Officer | 974 | $13.35 | $13.0K | Form 4 | |
| Feb 5, 2026 | Jennifer A. FoxChief Business Officer and Chief Financial Officer | 1,592 | $13.35 | $21.3K | Form 4 | |
| May 18, 2026 | Leon O Moulder JrChief Executive Officer | 60.0K | $16.88 | $1.0M | Form 4 | |
| Apr 29, 2026 | Leon O Moulder JrChief Executive Officer | 35.0K | $17.62 | $616.7K | Form 4 | |
| Apr 28, 2026 | Leon O Moulder JrChief Executive Officer | 25.0K | $18.02 | $450.5K | Form 4 | |
| Mar 31, 2026 | Hongbo Lu | 3,768 | $18.63 | $70.2K | Form 4 | |
| Mar 31, 2026 | Tomas Kiselak | 150.0K | $20.00 | $3.0M | Form 4 | |
| Mar 31, 2026 | Hongbo Lu | 75.0K | $20.00 | $1.5M | Form 4 | |
| Mar 31, 2026 | Leon O Moulder JrChief Executive Officer | 34.0K | $19.31 | $656.5K | Form 4 | |
| Mar 30, 2026 | Leon O Moulder JrChief Executive Officer | 20.0K | $18.23 | $364.6K | Form 4 | |
| Feb 13, 2026 | Patricia L Allen | 4,160 | $26.36 | $109.7K | Form 4 | |
| Feb 12, 2026 | Patricia L Allen | 5,000 | $26.50 | $132.5K | Form 4 | |
| Feb 12, 2026 | Patricia L Allen | 5,000 | $23.77 | $118.9K | Form 4 | |
| Feb 12, 2026 | Patricia L Allen | 5,700 | $24.34 | $138.7K | Form 4 | |
| Feb 11, 2026 | Hongbo Lu | 26.0K | $22.50 | $584.7K | Form 4 | |
| Feb 2, 2026 | Leon O Moulder JrChief Executive Officer | 57.0K | $17.96 | $1.0M | Form 4 | |
| Jan 9, 2026 | Leon O Moulder JrChief Executive Officer | 20.0K | $16.55 | $331.0K | Form 4 | |
| Jan 8, 2026 | Leon O Moulder JrChief Executive Officer | 30.0K | $16.30 | $489.0K | Form 4 | |
| Jan 7, 2026 | Leon O Moulder JrChief Executive Officer | 50.0K | $16.38 | $819.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ZBIO's officers and directors from 2024 up to November 21, 2025, 2 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class14.3%
- InnoCare Pharma Inc.with 2 more personsShare of class10.4%
- Wellington Management Group LLPwith 3 more personsShare of class10.1%
- SR One Capital Management, LLCwith 7 more personsShare of class7.70%
- Moulder Leon O Jrwith 2 more personsShare of class5.09%
- BlackRock, Inc.Share of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 14.3% | 7.65M | Feb 5, 20264 filings since May 12, 2025 | 13G/A | |
| InnoCare Pharma Inc.with 2 more persons | 10.4% | 7.00M | Sep 8, 20262 filings since Oct 15, 2025 | 13G/A | |
| Wellington Management Group LLPwith 3 more persons | 10.1% | 6.57M | Sep 8, 2026 | 13G | |
| SR One Capital Management, LLCwith 7 more persons | 7.70% | 5.04M | Aug 17, 20262 filings since Oct 14, 2025 | 13D/A | |
| Moulder Leon O Jrwith 2 more persons | 5.09% | 3.22M | May 5, 20265 filings since Jun 6, 2025 | 13D | |
| BlackRock, Inc. | 5.00% | 3.29M | Oct 27, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
SR One Capital Management, LLC7.7%From the filing of Oct 14, 2025
The Funds acquired their respective shares for investment purposes. Depending on market conditions, their continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a…
From the filing of Oct 14, 2025Moulder Leon O Jr5.1%From the filing of May 5, 2026
The information set forth in Item 3 of this Statement is incorporated herein by reference. Mr. Moulder serves as the Chairman of the Issuer's Board of Directors and as its Chief Executive Officer. In such capacity, Mr. Moulder has influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons reserve the right to formulate in the future plans…
From the filing of May 5, 2026
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter+512%
- Citadel Advisors (Griffin)In the quarter
- Millennium Mgmt (Englander)In the quarter-71%
- AQR CapitalIn the quarter-17%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 98.8K | +512% | $2.7M | 0.00% |
| Citadel Advisors (Griffin) | – | – | 0.00% | |
| Millennium Mgmt (Englander) | 194.1K | -71% | $5.2M | 0.00% |
| AQR Capital | 25.9K | -17% | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 18.5% of its shares outstanding were held short, +5.0% since the report before.
- Shares held short
- 12.54M
- 18.5%
- Since the report before11.94M on Sep 30, 2026
- +5.0%
- 18.8
- 666.1K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 99%
- Report date
- Oct 15, 2026
- Shares held short
- Sep 30, 2024: Shares held short 230.6K
- Oct 15, 2024: Shares held short 408.9K
- Oct 31, 2024: Shares held short 635.7K
- Nov 15, 2024: Shares held short 799.4K
- Nov 29, 2024: Shares held short 1.47M
- Dec 13, 2024: Shares held short 2.13M
- Dec 31, 2024: Shares held short 3.22M
- Jan 15, 2025: Shares held short 3.34M
- Jan 31, 2025: Shares held short 3.30M
- Feb 14, 2025: Shares held short 3.47M
- Feb 28, 2025: Shares held short 3.41M
- Mar 14, 2025: Shares held short 3.74M
- Mar 31, 2025: Shares held short 3.83M
- Apr 15, 2025: Shares held short 4.39M
- Apr 30, 2025: Shares held short 4.87M
- May 15, 2025: Shares held short 4.92M
- May 30, 2025: Shares held short 4.86M
- Jun 13, 2025: Shares held short 4.91M
- Jun 30, 2025: Shares held short 5.10M
- Jul 15, 2025: Shares held short 5.07M
- Jul 31, 2025: Shares held short 5.23M
- Aug 15, 2025: Shares held short 5.27M
- Aug 29, 2025: Shares held short 5.76M
- Sep 15, 2025: Shares held short 5.55M
- Sep 30, 2025: Shares held short 5.62M
- Oct 15, 2025: Shares held short 4.34M
- Oct 31, 2025: Shares held short 4.77M
- Nov 14, 2025: Shares held short 4.61M
- Nov 28, 2025: Shares held short 4.86M
- Dec 15, 2025: Shares held short 4.95M
- Dec 31, 2025: Shares held short 4.78M
- Jan 15, 2026: Shares held short 6.09M
- Jan 30, 2026: Shares held short 6.57M
- Feb 13, 2026: Shares held short 7.80M
- Feb 27, 2026: Shares held short 8.02M
- Mar 13, 2026: Shares held short 7.71M
- Mar 31, 2026: Shares held short 9.36M
- Apr 15, 2026: Shares held short 10.22M
- Apr 30, 2026: Shares held short 10.85M
- May 15, 2026: Shares held short 10.69M
- May 29, 2026: Shares held short 10.88M
- Jun 15, 2026: Shares held short 11.13M
- Jun 30, 2026: Shares held short 12.20M
- Jul 15, 2026: Shares held short 12.17M
- Jul 31, 2026: Shares held short 11.75M
- Aug 14, 2026: Shares held short 11.66M
- Aug 31, 2026: Shares held short 11.70M
- Sep 15, 2026: Shares held short 11.87M
- Sep 30, 2026: Shares held short 11.94M
- Oct 15, 2026: Shares held short 12.54M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading67.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 67.4% of the shares in the reported trades were short sales, against 61.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 67.4%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 61.9%
- Change
- +5.5 pts
- Short sales a dayon average, of 200.7K shares
- 135.3K
- More than atof 3,666 US-listed companies, same days
- 95%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 58.3%
- Oct 15, 2026: Short sales 34%
- Oct 16, 2026: Short sales 79.6%
- Oct 19, 2026: Short sales 76.3%
- Oct 20, 2026: Short sales 70.8%
- Oct 21, 2026: Short sales 66.9%
- Oct 22, 2026: Short sales 55.3%
- Oct 23, 2026: Short sales 51.8%
- Oct 26, 2026: Short sales 57.2%
- Oct 27, 2026: Short sales 70.7%
- Oct 28, 2026: Short sales 66.9%
- Oct 29, 2026: Short sales 64%
- Oct 30, 2026: Short sales 51.1%
- Nov 2, 2026: Short sales 39.6%
- Nov 3, 2026: Short sales 45.6%
- Nov 4, 2026: Short sales 39.5%
- Nov 5, 2026: Short sales 76%
- Nov 6, 2026: Short sales 82.4%
- Nov 9, 2026: Short sales 66.4%
- Nov 10, 2026: Short sales 77.9%
- Nov 11, 2026: Short sales 48%
- Nov 12, 2026: Short sales 64.8%
- Nov 13, 2026: Short sales 81.3%
- Nov 16, 2026: Short sales 81.3%
- Nov 17, 2026: Short sales 72.7%
- Nov 18, 2026: Short sales 66.6%
- Nov 19, 2026: Short sales 69.3%
- Nov 20, 2026: Short sales 82.9%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Zebra Aggregator, LPTenPercentOwnerDirectly–
- Tomas KiselakDirectorDirectly–
- Peter Evan HarwinDirectorDirectly–
- Fairmount Funds Management LLCDirectorDirectly–
- Patrick G EnrightDirectorDirectly12.0K
- Sr One Capital Management, LlcTenPercentOwnerDirectly–
- Jason Raleigh NunnDirectorDirectly–
- Leon O Moulder JrChief Executive OfficerDirectly423.2K
- Hongbo LuDirectorDirectly–
- Patricia L AllenDirectorDirectly19.9K
- Ting XiaoDirectorDirectly10.0K
- Jennifer A. FoxChief Business Officer and Chief Financial OfficerDirectly1,592
- Joseph L FarmerPresident and Chief Operating OfficerDirectly974
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Zebra Aggregator, LPTenPercentOwner | – | 3.76M | Sep 16, 2024 | Form 4 |
| Tomas KiselakDirector | – | 2.36M | Mar 31, 2026 | Form 4 |
| Peter Evan HarwinDirector | – | 2.21M | Oct 7, 2025 | Form 4 |
| Fairmount Funds Management LLCDirector | – | 1.89M | Sep 16, 2024 | Form 4 |
| Patrick G EnrightDirector | 12.0K | 1.83M | Oct 9, 2025 | Form 4 |
| Sr One Capital Management, LlcTenPercentOwner | – | 1.17M | Oct 9, 2025 | Form 4 |
| Jason Raleigh NunnDirector | – | 1.17M | Oct 9, 2025 | Form 4 |
| Leon O Moulder JrChief Executive Officer | 423.2K | 96.9K | May 18, 2026 | Form 4 |
| Hongbo LuDirector | – | 426.7K | Mar 31, 2026 | Form 4 |
| Patricia L AllenDirector | 19.9K | – | Feb 13, 2026 | Form 4 |
| Ting XiaoDirector | 10.0K | – | Feb 7, 2025 | Form 4 |
| Jennifer A. FoxChief Business Officer and Chief Financial Officer | 1,592 | – | Feb 5, 2026 | Form 4 |
| Joseph L FarmerPresident and Chief Operating Officer | 974 | – | Feb 5, 2026 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.32%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.29%
- IWCiShares Micro-Cap ETFWeight in the fund0.16%
- IBBiShares Biotechnology ETFWeight in the fund0.06%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.04%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
17 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 80
- Q4 2025: Managers 119
- Q1 2026: Managers 140
- Q2 2026: Managers 145
Institutional investors by quarter
The fund managers holding ZBIO, quarter by quarter, from Q2 2015 to Q2 2025, 24 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 145 managers held 61.27M shares, worth $1.5B. During the quarter 29 opened a position, 24 closed one, 57 added and 38 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+4.7%
- SR One Capital ManagementIn the quarter
- NEA ManagementIn the quarter
- Enavate Sciences GpIn the quarter
- Federated HermesIn the quarter-0.3%
- BlackRockIn the quarter+32%
- Capital International InvestorsIn the quarter+2.8%
- Polar Capital HoldingsIn the quarter-5.3%
- Royalty Pharma Sub-ManagerIn the quarter
- Fairmount Funds ManagementIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 9.51M | +4.7% | $241M |
| SR One Capital Management | 5.04M | $128M | |
| NEA Management | 4.02M | $102M | |
| Enavate Sciences Gp | 3.92M | $99M | |
| Federated Hermes | 3.12M | -0.3% | $79M |
| BlackRock | 2.69M | +32% | $68M |
| Capital International Investors | 2.50M | +2.8% | $64M |
| Polar Capital Holdings | 2.41M | -5.3% | $61M |
| Royalty Pharma Sub-Manager | 2.39M | $61M | |
| Fairmount Funds Management | 2.36M | $60M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Zenas BioPharma's filings show?
Who buys and sells is one part of Zenas BioPharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ZBIO's insiders bought or sold?
From Jun 17, 2026 to Sep 2, 2026 Zenas BioPharma's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold ZBIO?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $5.2M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.